about
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugsCurrent evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis.Treating rheumatoid arthritis to target: recommendations of an international task force.Clinical and radiographic outcomes at 2 years and the effect of tocilizumab discontinuation following sustained remission in the second and third year of the ACT-RAY study.American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire.Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions.Prevalence of comorbidities in rheumatoid arthritis and evaluation of their monitoring: results of an international, cross-sectional study (COMORA).Infectious complications of biologic agents.Evidence for treating rheumatoid arthritis to target: results of a systematic literature search.Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study.The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel.New drugs beyond biologics in rheumatoid arthritis: the kinase inhibitors.The role of biosimilars in the treatment of rheumatic diseases.Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task forceAnti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.Patients' and rheumatologists' preferences for the attributes of biological agents used in the treatment of rheumatic diseases in Spain.Development of multinational definitions of minimal clinically important improvement and patient acceptable symptomatic state in osteoarthritis.Assessment of Global Disease Activity in Rheumatoid Arthritis by Patients and Physicians: Differences Across Countries in the METEOR Database.The Minimum Clinically Important Improvement and Patient-acceptable Symptom State in the BASDAI and BASFI for Patients with Ankylosing Spondylitis.Sustained remission with etanercept tapering in early rheumatoid arthritis.Etanercept in the longterm treatment of patients with ankylosing spondylitis.Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists.Adaptation of the osteoarthritis-specific quality of life scale (the OAQoL) for use in Germany, Hungary, Italy, Spain and Turkey.Influence of immunogenicity on the efficacy of longterm treatment of spondyloarthritis with infliximab.Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008.IL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumab.Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trialEffectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 StudyTofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid ArthritisThe impact of a jointly staffed clinic on the diagnosis of lung involvement and connective tissue diseasesEffectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double-blind, Phase 3b Study
P50
Q34110066-C736E4EA-3A07-48B6-9456-EDF7D3CCF72CQ34113970-3975D2CC-6952-478A-B42E-A1322B41C7DEQ34462557-37181BE7-EB51-410A-89AF-534D18F31A79Q34818996-555A8AA7-9C02-441A-81C4-63E0D3B86B06Q35047250-14179BE2-BCE0-451E-8784-4B6FB2D561D1Q35740447-887FF44C-3991-46BD-A540-65953B654D78Q36677277-1DD240A7-4A3E-44F3-8B0C-B70B291C5A93Q37465556-3AFD4BCC-4E6F-4CE8-A47B-6C3E89C1DBB2Q37500817-4BD6C5BC-8230-49AB-A500-8AD35DEA7914Q37710906-89F5F59A-E96D-48CA-9443-2FB772D4112EQ37715956-0BE28D74-0AD4-4CC0-9AE3-25765FB5D427Q37787639-928B276F-D206-4403-BE22-F0ACF37AD8B8Q37881775-A36C07C3-61DC-4B88-A8A6-8C3ED99549C5Q38068691-4F0F8183-1623-4B72-9663-0A92C2F782FFQ38476881-D4A2AAE3-D335-4411-BBE2-E3D9198DBABAQ38857820-A5854B90-7C2A-4900-8B59-7F92DC878A27Q38887484-94949029-C661-41C4-A13F-DFF4CD5C3961Q38901250-F615CCFD-8809-4D10-B22A-98DDA50369BCQ40510582-DAA3330D-65ED-4503-BC28-44DF8DF45207Q40698907-F8DE2E22-5F52-43A1-BA60-A9CF4D153946Q41676104-3C8D20C2-DF94-4D67-928A-79D04880FAA2Q42619535-2D7D71F1-DA67-450D-85D9-B1AC9E7E1085Q46525959-62D9DA95-044A-462C-B3B3-6584B7899993Q47575273-0F719CBD-BF04-45D0-92DB-5D3C73E4D054Q50758911-049BFCC6-6EFC-4AA2-A6BC-56E8BA3533D4Q53107015-E36076FF-259F-4B1B-93CA-3A5EFCD5F061Q55058284-82A78BC0-7186-4506-9DD2-A8B6331080A6Q56334428-7B5C46C7-FA53-4F6C-BB51-45E993BC7AFBQ58912037-2F279786-A51A-48F2-A22C-A4A1CC93CB45Q60061984-146E981C-1491-4704-9227-3A1ACAB468E8Q82294983-D6420E42-D34F-451E-8032-B478E5FE3360Q87693527-0043875D-A688-461E-816C-2B043946BA17
P50
name
Emilio Martin-Mola
@en
type
label
Emilio Martin-Mola
@en
prefLabel
Emilio Martin-Mola
@en
P2038
Emilio_Martin-Mola